In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Corvus Pharmaceuticals Inc. Trade Record

NASDAQ:CRVS Corvus Pharmaceuticals Inc stock gains 29.00% Exit Apr 4, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart CRVS Mar 8, 2017, priceSeries
About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
99.60
Entry Date
Mar 8, 2017
Entry Price
15.57
Sell Date
Apr 4, 2017
Sell Price
20.09
Net Gain
29.00%
Hold Time
19 Trading Days